The changes in cardiovascular score values and their influencing factors after 24 weeks of treatment with acarbose and metformin based on the MARCH data
Objective:To analyze the changes in cardiovascular score values and their influencing factors af-ter 24 weeks of treatment with acarbose and metformin in the MARCH(Metformin and AcaRbose in Chinese as the initial Hypoglycaemic treatment)study.Methods:A total of 784 patients were entered into the MARCH database,and 152 patients with incomplete index information were excluded.In this study,632 patients in the database who were randomized to receive acarbose(n=325)and metformin(n=307)for 24 weeks were selected to have cardiovascular scores,and their ADVANCE 4-year cardiovascular event risk score values at baseline and at 24 weeks of treatment were calculated and the degree of improvement,and univariate and multivariate linear regression analyses were applied to determine the influencing factors associated with the rate of change in score values(Δscore%).Results:After 24 weeks of treatment in 632 patients,the score values of both groups improved from baseline(P<0.05),with no statistical difference between the two groups(P>0.05),and the triglyceride values at baseline significantly affected Δscore%(P<0.05).Conclusion:Both acarbose and metformin can significantly improve the 4-year cardiovascular risk score values of Chinese patients with type 2 diabetes mellitus,and the effects were similar in both groups.Triglyceride values can significantly affect the rate of change of score values.
type 2 diabetes mellitusacarbosemetformincardiovascular risk score